However, only a few of them, namely small inhibitors, mAbs, and miRNAs, have been tested so far in the context of AD, giving promising results in reversing PCSK9 pleiotropic activities known to compromise cerebral physiology. This evidence concerns the gene PCSK9 and Alzheimer disease.